| NCT ID | NCT04360200 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yamei Tang |
| Condition | MCI |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2020-04-01 |
| Primary Completion | 2040-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2020-04-01 with a primary completion date of 2040-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood/CSF biomarkers for the early detection and tracking of cognitive disorders.
Eligibility Criteria
Inclusion Criteria: 1. Patients over 50 years old. 2. Sign informed consent. 3. According to DSM-IV, the diagnostic standard of dementia was not met. 4. The clinical dementia rating (CDR) was 0.5. Exclusion criteria: 1. Subjects with mental retardation. 2. Refuse to have blood sampling, imaging and other examinations. 3. Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia). 4. Contraindications of MR scanning. 5. Suffering from serious physical or mental illness.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04360200 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying MCI. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04360200 currently recruiting?
Yes, NCT04360200 is actively recruiting participants. Contact the research team at yameitang@hotmail.com for enrollment information.
Where is the NCT04360200 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT04360200 clinical trial?
NCT04360200 is sponsored by Yamei Tang. The trial plans to enroll 5,000 participants.